Bionomics Limited American Depository Shares
BNOX Real Time Price USDRecent trades of BNOX by members of U.S. Congress
No Congress Trading data for this ticker
Congress Trading Dashboard
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
---|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Recently reported changes by institutional investors
Quarterly net insider trading by BNOX's directors and management
Government lobbying spending instances
No Corporate Lobbying instances for this ticker
Corporate Lobbying DashboardEstimated quarterly lobbying spending
No Corporate Lobbying data for this ticker
Corporate Lobbying DashboardNew patents grants
-
Patent Title: Substituted-n-heteroaryl compounds and uses thereof Nov. 12, 2024
-
Patent Title: Substituted-pyridinyl compounds and uses thereof Sep. 17, 2024
-
Patent Title: Modulators of ion channel receptors and uses thereof Jan. 30, 2024
-
Patent Title: Antibody and checkpoint inhibitor combination therapy May. 23, 2023
-
Patent Title: Method for treating acute myeloid leukemia Oct. 25, 2022
-
Patent Title: Modulators of ion channel receptors and uses thereof Jul. 12, 2022
-
Patent Title: Anxiolytic compounds Mar. 23, 2021
-
Patent Title: Method of treating cancer by administering an anti-lgr5 monoclonal antibody Aug. 18, 2020
-
Patent Title: Predictive biomarkers Feb. 18, 2020
-
Patent Title: Predictive baseline biomarkers for use of vascular disrupting agents Dec. 31, 2019
-
Patent Title: Humanized antibodies that bind lgr5 Jul. 23, 2019
-
Patent Title: Salts, co-crystals, and polymorphs of an anxiolytic compound Apr. 23, 2019
-
Patent Title: Anxiolytic compounds Mar. 19, 2019
-
Patent Title: Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors Feb. 26, 2019
-
Patent Title: Methods of inhibiting growth of a colon cancer tumor in a subject by administering monoclonal antibodies to g protein-coupled receptor 49 (gpr49) Feb. 05, 2019
-
Patent Title: Predicting response to cancer therapy Dec. 25, 2018
-
Patent Title: Combination treatment protocol Nov. 27, 2018
-
Patent Title: Method for treating chronic lymphocytic leukemia Jun. 05, 2018
-
Patent Title: Anxiolytic compounds May. 22, 2018
-
Patent Title: Amine derivatives as potassium channel blockers Mar. 13, 2018
-
Patent Title: Crystalline form of an anxiolytic compound Sep. 12, 2017
-
Patent Title: Salts, co-crystals, and polymorphs of an anxiolytic compound Aug. 29, 2017
-
Patent Title: Antibodies that bind lgr4, their use in inhibiting neoplastic cells and in treating tumors Apr. 25, 2017
-
Patent Title: Anxiolytic compounds Feb. 21, 2017
-
Patent Title: Humanized antibodies that bind lgr5 Jan. 17, 2017
-
Patent Title: Amine derivatives as potassium channel blockers Nov. 15, 2016
-
Patent Title: Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors May. 24, 2016
-
Patent Title: Anti-gpr49 monoclonal antibodies Dec. 29, 2015
-
Patent Title: Methods of inhibiting solid tumor growth by administering gpr49 antibodies Dec. 29, 2015
-
Patent Title: Methods of treating cancer by administering anti-gpr49 antibodies Dec. 29, 2015
-
Patent Title: Methods for preparing naphthyridines Sep. 15, 2015
-
Patent Title: Positive allosteric modulators of the α7 nicotinic acetylcholine receptor and uses thereof Jun. 23, 2015
-
Patent Title: Small-molecules as therapeutics May. 05, 2015
-
Patent Title: Combination therapy for treating proliferative diseases Apr. 14, 2015
-
Patent Title: Anxiolytic compounds Dec. 09, 2014
-
Patent Title: Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors May. 06, 2014
-
Patent Title: Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors Mar. 25, 2014
-
Patent Title: Chemical processes for the manufacture of substituted benzofurans Mar. 18, 2014
-
Patent Title: Anxiolytic compounds Dec. 24, 2013
-
Patent Title: Tubulin polymerisation inhibitors Oct. 15, 2013
-
Patent Title: Anxiolytic compounds Oct. 08, 2013
-
Patent Title: Potassium channel blockers and uses thereof Aug. 13, 2013
-
Patent Title: Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization Jun. 18, 2013
-
Patent Title: Benzofuran potassium channel blockers and uses thereof Nov. 13, 2012
-
Patent Title: Methods of identifying agents that inhibit angiogenesis Nov. 13, 2012
-
Patent Title: Anxiolytic compounds Oct. 23, 2012
-
Patent Title: Diagnostic method for epilepsy Oct. 16, 2012
-
Patent Title: Chromenone potassium channel blockers and uses thereof Jul. 10, 2012
-
Patent Title: Aryl potassium channel blockers and uses thereof Jun. 19, 2012
-
Patent Title: Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors Jun. 12, 2012
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of BNOX in WallStreetBets Daily Discussion
Recent insights relating to BNOX
Recent picks made for BNOX stock on CNBC
ETFs with the largest estimated holdings in BNOX
Shareholder
|
Shares Held
|
---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BNOX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.